findmyKOL
Clinical trialNCT00796705TerminatedPhase 4Interventional

Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment13Rheumatoid Arthritis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Rheumatoid Arthritis (RA) is a systemic inflammatory autoimmune disorder that leads to inflammation and progressive joint damage affecting 2.5 million people in the United States. The primary purpose of this study is to determine the effectiveness of switching to an alternative Tumor Necrosis Factor (TNF) alpha inhibitor in comparison to continuing treatment with an existing TNF-alpha inhibitor in adults suffering from RA in a setting of inadequate clinical response to etanercept or adalimumab.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama

    Birmingham, Alabama, United States

  • Stanford University

    Palo Alto, California, United States

  • Yale New Haven Hospital

    New Haven, Connecticut, United States

  • Sarasota Arthritis Research Center

    Sarasota, Florida, United States

  • Tampa Medical Group

    Tampa, Florida, United States

  • University of Chicago Medical Center

    Chicago, Illinois, United States

  • Justus Fiechtner, Md, Pc

    Lansing, Michigan, United States

  • Feinstein Institute for Medical Research Ns-Lij

    Manhassett, New York, United States

  • University of Rochester

    Rochester, New York, United States

  • Carolina Bone and Joint

    Charlotte, North Carolina, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • Oklahoma Medical Research Foundation

    Oklahoma City, Oklahoma, United States

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, United States

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, United States

  • Baylor Research Institute

    Dallas, Texas, United States

  • University of Utah

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Adalimumab →Adalimumab placeboEtanercept →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2008
Primary completion
31 Oct 2010
Completion
31 Oct 2010
Last update posted
4 Oct 2012
Registered enrollment
13
Registry id
NCT00796705
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.